Controlling protein production in brain cells could help treat Parkinson’s
New research has been published that sheds an important light on how the production of a key protein in the brain is controlled This could pave the way for new treatments for a wide range of neurological conditions.
Scientists move closer to developing ‘game-changing’ test to diagnose Parkinson’s
Research shows it’s possible to identify Parkinson’s based on compounds found on the surface of skin. The findings offer hope that the condition could be diagnosed through a simple swab test.
We're investing £1.2m into drug that could slow Parkinson's
We’re investing up to £1.2m into pioneering research in partnership with the University of Sheffield, which aims to develop a drug to protect dopamine-producing brain cells.
Why we’re committing £800,000 to plan a new GDNF trial
The earlier groundbreaking clinical trial proved inconclusive. So we’re launching a new company tasked with planning a possible new trial.
Further clues about alpha-synuclein
New research has advanced our understanding of a protein called alpha-synuclein, which is believed to play a central role in damaging brain cells in Parkinson’s.
Vision tests predict cognitive decline linked to Parkinson's
Scientists in the UK have uncovered evidence that simple vision tests can predict who will develop Parkinson's dementia. And the evidence shows that a loss of wiring in the brain may be the cause.
New guidance for lab-based researchers on patient and public involvement
We’ve partnered with Alzheimer’s Society and University College London Hospitals (UCLH) Biomedical Research Centre. Together, we’ve developed a new resource to help lab-based researchers with patient and public involvement (PPI).
Levodopa-making tomatoes could provide an affordable medication for Parkinson's symptoms
Scientists in the UK have developed a tomato plant that produces high levels of levodopa. This research may help more people access this important Parkinson's medication.
New trial to drive forward promising treatment for dyskinesia
Parkinson’s UK is joining forces with US charity The Michael J. Fox Foundation and biopharma company Neurolixis to fund a £1.5m clinical trial of an exciting new drug to combat dyskinesia in people with Parkinson’s.